ERBB2 and cancer: This pan-cancer trial cohort includes patients with locally advanced or metastatic solid tumors with EGFR or HER2 exon 20 insertion mutations, in addition to allosteric HER2/HER3 mutations, HER2 amplification, or EGFR exon 19 deletion or L858R mutation.